Glaukos Corporation GKOS
Analyst Ratings
- Consensus
- Buy — 11 Buy · 1 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $224.42 (-7.4% downside)
Key Stats
- Today's Range
- $207.41 – $243.71
- 50-Day Range
- $146.38 – $243.71
- 52-Week Range
- $73.16 – $243.71
- Volume
- 5.42 million shs
- Average Volume
- 1.20 million shs
- Market Cap
- $10.70 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 6.71%
- Days to Cover
- 12.82
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Related Stocks
Compare head-to-head: GKOS vs SYK·GKOS vs BSX·GKOS vs RMD·GKOS vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.